David Urech to join the board

BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Aukera Therapeutics, a preclinical-stage biotech spin-off from the University of Basel is officially coming out of stealth as it enters preclinical efficacy studies. It announced today that it has raised some CHF 4.5M to date and attracted new board member and investor David Urech. Other current investors include Kickfund and Zürcher Kantonalbank.

Aukera is focused on the therapy of neurological conditions associated with RAPTOR activity (regulatory-associated protein of mTOR). The company screened billions of compounds using AI-supported technology to discover a highly selective RAPTOR inhibitor modulating the mTORC1 signaling network – a new approach to selectively tackling a proven target with the potential for greater efficacy and favorable safety.

Aukera CEO and co-founder, Stefan Imseng, Ph.D., is pledging to pursue a therapy in Tuberous Sclerosis Complex (TSC), a rare multisystem genetic disorder.

“TSC typically starts in infancy and leads to seizures and a plethora of neuropsychiatric symptoms,” said Stefan, adding that mutations in TSC genes overactivate mTORC1 and lead to hyperexcitability of neurons in the brain. “Aukera’s RAPTOR inhibitors dampen mTORC1 activity, which is expected to result in reduced frequency and severity of seizures, offering relief for TSC patients, families and caregivers.”

The company plans to expand later to other indications with mTORC1 dysregulation, such as neurodegeneration, metabolic disorders, age-related diseases.

“The promise to change the lives of more than one million TSC patients, and the scientific excellence of the Aukera team, is why I decided to invest and join the board,” said David Urech, founder and former CEO of Numab Therapeutics whose subsidiary Yellow Jersey sold to J&J for $1.25 B in 2024.

About Aukera Therapeutics
Aukera Therapeutics is developing the first RAPTOR inhibitors for the treatment of mTORC1-related pathologies. The company is a spin-off from the Biozentrum of the University of Basel, founded on seminal academic research from the laboratories of Professors Michael N. Hall and Timm Maier. Aukera pairs mTOR expertise with an AI-driven drug discovery engine built for complex and hard-to-drug targets. The company’s lead program focuses on rare neurological disorders such as TSC. Future use of RAPTOR inhibitors include neurodegenerative, metabolic and age-related diseases. Aukera has received funding and support from Venture Kick, BaseLaunch, the Innovation Office of the University of Basel and Innosuisse.

Investor and media inquiries:
Aukera Therapeutics	O public relations GmbH
Stefan Imseng	O’Patrick Wilson
media@aukera-tx.com	o@os-pr.com

+41 61 207 6081	+41 78 888 4332

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0fa1d97a-8a6a-459d-8754-fc61e33c284f

This item of content is a press release from a third party provider who make no warranties or representations in connection with this content and therefore PA can make no warranties in respect of its use.

Tags

More Like This

Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025

EQT Life Sciences co-leads USD 39 million Series A in Aerska to help systematically deliver RNA medicines to the brain

Aukera Closes €460 Million Structured Credit Facility Led by EIG to Support European Energy Infrastructure Portfolio

Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca

Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout

Arctic Therapeutics Announces €26.5M Oversubscribed Series A Financing

EQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics company, as part of USD 100 million Series C financing round

Akura Medical, a Shifamed Portfolio Company, Closes $53 Million in Series C Financing